Business
Lantern Pharma Leverages AI Platform, RADR®, to Develop Breakthrough Antibody Drug Conjugates (ADCs) in Collaboration with Bielefeld University
Lantern will leverage its proprietary AI platform, RADR®, to rapidly develop novel cryptophycin-antibody drug conjugates (ADCs), which represent an exciting
About this update from Lantern Pharma Inc.
[{"type":"text","content":"\n\nLantern will leverage its proprietary AI platform, RADR®, to rapidly develop novel cryptophycin-antibody drug conjugates (ADCs), which represent an exciting class of potent and highly targeted drug candidates.\n\n\n\nThe collaboration with Bielefeld University (Germany) will be led by Professor Norbert Sewald, Ph.D., a leading expert in the synthesis of cryptophycins, development of ADCs, and the coordinator of the “Magicbullet::reloaded” consortium.\n\n\n\nThe global ADC market is currently over $4.0 billion and is projected to reach $14.0 billion by 2027.\n\n\n\nLantern is receiving an exclusive and worldwide option to license intellectual property from Bielefeld University related to the collaboration and IP generated from the collaboration.\n\n\n\n DALLAS--(BUSINESS WIRE)--\nLantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company using its proprietary RADR® artificial intelligence (\"AI\") and machine learning (“ML”) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced it will be leveraging its AI platform, RADR®, in a research collaboration with Bielefeld University (Bielefeld, Germany) to develop antibody-drug conjugates (ADCs) with high therapeutic and antitumor potential. The collaboration will leverage insights from Lantern’s recently developed RADR® AI ADC module in combination with research from Professor Norbert Sewald, Ph.D., the principal investigator for Bielefeld and leader of Magicbullet::reloaded, a European consortium focused on developing novel drug delivery mechanisms, including ADCs. Outcomes from the collaboration are expected to pave the way for next-generation ADCs and other drug conjugates that are designed using AI and that can be developed with potentially higher efficacy, at a faster pace, and with significantly reduced costs.\n\nThis press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230608005298/en/The global ADC market is currently over $4.0 billion and is projected to reach $14.0 billion by 2027 (Graphic: Business Wire)\nThe initial aim of the collaboration will be to synthesize and evaluate novel ADCs linked to cryptophycins, which are promising antitumor molecules, in part because of their potency at ultra-low, picomolar, concentrations. The cryptophycin-ADCs...